Capital Fund Management (CFM)
BCRX icon

Capital Fund Management (CFM)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Sell
33,327
-23,811
-42% -$215K ﹤0.01% 1966
2026
Q1 		$544K Buy
+57,138
New +$444K ﹤0.01% 1857
2025
Q3 		– Sell
-51,913
Closed -$465K – 2436
2025
Q2 		$465K Buy
+51,913
New +$483K ﹤0.01% 2205
2025
Q1 		– Sell
-59,327
Closed -$446K – 1985
2024
Q4 		$446K Sell
59,327
-298,288
-83% -$2.26M ﹤0.01% 1928
2024
Q3 		$2.72M Buy
357,615
+110,075
+44% +$837K 0.01% 1289
2024
Q2 		$1.53M Buy
247,540
+36,009
+17% +$199K ﹤0.01% 1482
2024
Q1 		$1.07M Buy
+211,531
New +$1.19M ﹤0.01% 1688
2023
Q4 		– Sell
-122,778
Closed -$869K – 2102
2023
Q3 		$869K Sell
122,778
-46,910
-28% -$337K ﹤0.01% 1686
2023
Q2 		$1.19M Buy
169,688
+104,394
+160% +$838K ﹤0.01% 1353
2023
Q1 		$545K Buy
+65,294
New +$629K ﹤0.01% 1432
2022
Q2 		– Sell
-117,505
Closed -$1.91M – 1421
2022
Q1 		$1.91M Buy
+117,505
New +$1.88M 0.02% 965
2014
Q3 		– Sell
-38,904
Closed -$496K – 1519
2014
Q2 		$496K Buy
+38,904
New +$379K 0.01% 1215

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Capital Fund Management (CFM)'s BCRX Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its BioCryst Pharmaceuticals (BCRX) stake by 42% in Q2 2026, selling an estimated $215K and leaving 33,327 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Capital Fund Management (CFM) first reported a position in BCRX in Q2 2014 and has held it in 12 quarters since. The position peaked at $2.72M in Q3 2024. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Capital Fund Management (CFM) held 33,327 shares of BioCryst Pharmaceuticals worth $333K as of Q2 2026.
  • Capital Fund Management (CFM) sold 23,811 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $215K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1966 holding.
  • Capital Fund Management (CFM) first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
  • Capital Fund Management (CFM)'s BioCryst Pharmaceuticals position peaked at $2.72M in Q3 2024.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.